ST034307 is a selective inhibitor of adenylyl cyclase 1 (AC1) with analgesic activity. Adenylyl cyclase 1 has been shown to be a potential target for treating pain and reducing the dependency on opioids, but it has been difficult to inhibit AC1 selectively without also inhibiting other isoforms vital to physiological functions. ST034307 is selective for AC1 over all eight other adenylyl cyclase isoforms. It inhibited AC1 and reduced cAMP, while leaving AC8 unaffected and was shown to reduce pain in a mouse inflammatory pain model.
Selective inhibitor of adenylyl cyclase 1 (AC1) with analgesic activity
Bacterial infection is a dynamic process resulting in a heterogenous population of infected and uninfected cells. These cells respond differently based on their bacterial load and duration of infection. In the case of infection of macrophages with Crohn's disease (CD)
Adenylyl cyclase 1 (AC1) belongs to a group of adenylyl cyclases (ACs) that are stimulated by calcium in a calmodulin-dependent manner. Studies with AC1 knockout mice suggest that inhibitors of AC1 may be useful for treating pain and opioid dependence.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
